Statements (51)
| Predicate | Object |
|---|---|
| gptkbp:instance_of |
gptkb:drug
|
| gptkbp:activities |
inhibits dihydrofolate reductase
inhibits thymidylate synthase |
| gptkbp:appointed_by |
intravenous injection
|
| gptkbp:approves |
gptkb:2004
gptkb:FDA |
| gptkbp:can_be_used_with |
gptkb:cisplatin
gptkb:carboplatin |
| gptkbp:clinical_trial |
Phase III
|
| gptkbp:contraindication |
pregnancy
breastfeeding hypersensitivity to pemetrexed |
| gptkbp:financial_products |
D B00966
|
| https://www.w3.org/2000/01/rdf-schema#label |
Alimta
|
| gptkbp:indication |
gptkb:malignant_pleural_mesothelioma
recurrent non-small cell lung cancer |
| gptkbp:ingredients |
gptkb:pemetrexed
C15 H21 N3 O6 S |
| gptkbp:interacts_with |
vitamin B12
NSAI Ds folic acid supplements |
| gptkbp:is_atype_of |
L01 B A04
|
| gptkbp:is_available_on |
gptkb:brand
|
| gptkbp:is_monitored_by |
liver function tests
renal function complete blood count |
| gptkbp:is_used_for |
treatment of non-small cell lung cancer
treatment of mesothelioma |
| gptkbp:manager |
IV
|
| gptkbp:market |
available in many countries
|
| gptkbp:marketed_as |
gptkb:Eli_Lilly_and_Company
|
| gptkbp:packaging |
vial
|
| gptkbp:pharmacokinetics |
excretion primarily in urine
half-life 3.5 hours protein binding 81% |
| gptkbp:price |
varies by country and insurance
|
| gptkbp:requires |
prescription only
|
| gptkbp:scholarships |
stay hydrated
report any signs of infection avoid pregnancy during treatment |
| gptkbp:side_effect |
gptkb:fandom
fatigue nausea diarrhea loss of appetite |
| gptkbp:status |
ongoing clinical trials
|
| gptkbp:storage |
room temperature
|
| gptkbp:type_of |
137280-66-4
|
| gptkbp:weight |
345.41 g/mol
|
| gptkbp:bfsParent |
gptkb:Eli_Lilly_and_Company
|
| gptkbp:bfsLayer |
3
|